3 Undervalued Pharmaceuticals Stocks for Friday, July 10
Discover the top 3 undervalued Pharmaceuticals stocks for Friday, July 10 based on AAII’s Stock Grades.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Commentary & Analysis
Why Arvinas, Inc.’s (ARVN) Stock Is Up 5.50%
As of Monday, June 29, Arvinas, Inc.’s ARVN share price has surged by 5.50%, which has investors questioning if this is right time to sell.Jenna Brashear
3 Undervalued Pharmaceuticals Stocks for Wednesday, June 10
Discover the top 3 undervalued Pharmaceuticals stocks for Wednesday, June 10 based on AAII’s Stock Grades.Rosalio Madrigal
Why Arvinas, Inc.’s (ARVN) Stock Is Down 5.25%
As of Wednesday, June 03, Arvinas, Inc.’s ARVN share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Arvinas, Inc.’s (ARVN) Stock Is Down 5.48%
As of Tuesday, June 02, Arvinas, Inc.’s ARVN share price has dipped by 5.48%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $518.1 | $579.1 | 38% |
|
| Shares Out (Mil) | 64.0 | 43.0 | 54% |
|
| Institutional Ownership | 96.7% | 84.3% | 71% |
|
| Float (Mil) | 55.8 | 46.8 | 50% |
|
| Beta | 1.80 | 0.62 | 89% |
|
| Avg Daily Volume (000s) | 592 | 285 | 62% |
|
| Price Change (52-week) |
5.9% | 63.8% | 50% |
|
| Growth | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 58.9% | 6.7% | 97% |
|
| Net Income (5yr) | 7.5% | (1.4%) | 51% |
|
| EPS (5yr) | 17.7% | 14.9% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.2%) | (14.9%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($0.283) | ($2.852) | ($3.333) | |
| Month Ago EPS | ($0.266) | ($2.864) | ($3.449) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 2 | 1 | |
| Three Months Ago EPS | ($0.622) | ($3.466) | ($3.524) | |
| Year/Year Chg | (68.6%) | 150.2% | 114.3% | |
| Financials | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $89 | $272 | 25% |
|
| Net Income (TTM) (Mil) | ($221) | ($11) | 6% |
|
| EPS (TTM) | ($3.218) | ($0.500) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($254) | ($6) | 3% |
|
| Net Cash Flow (TTM) (Mil) | $6 | $4 | 54% |
|
| Long-Term Debt (Q1) (Mil) | $7 | $7 | 26% |
|
| Enterprise Value (Q1) (Mil) | $11 | $522 | 8% |
|
| Valuation | ARVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.34 | 2.73 | 34% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 134.5% | 65.9% | 100% |
|
| Net Margin | (247.5%) | 0.7% | 4% |
|
| ROA | (26.8%) | (24.6%) | 18% |
|
| ROE | (42.3%) | (19.7%) | 17% |
|
| Liabilities to Assets | 40.3% | 35.5% | 31% |
|
| F-Score | 4 | 3 | 34% |
|
Arvinas, Inc. did not pass any screens on 7/31/2026.
